Restarting Jardiance (Empagliflozin) After Acute Illness: A Woman's Complete Guide

Why the Restart Question Matters More Than You Might Expect

Empagliflozin is not a drug you simply pause and resume without thought. The EMPA-REG OUTCOME trial showed a 38% reduction in cardiovascular death among adults with type 2 diabetes and established cardiovascular disease, making it one of the most consequential medications in modern cardiometabolic care. Missing doses costs you that protection. Restarting too soon, while you are still sick, dehydrated, or fasting, can trigger euglycemic diabetic ketoacidosis (DKA), a life-threatening emergency that is easy to miss because blood glucose may be only mildly elevated or even normal.

Women face a specific additional challenge: hormonal fluctuations across the menstrual cycle, perimenopause, and the postpartum period all shift insulin sensitivity and ketone production in ways that change your individual DKA risk profile. This guide gives you the clinical framework to stop, hold, and restart empagliflozin safely, with attention to where you are in your reproductive life.

How Empagliflozin Works and Why Illness Changes Everything

Empagliflozin blocks the sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule of the kidney, causing the body to excrete roughly 60 to 80 grams of glucose per day in the urine. That glucosuria drives modest osmotic diuresis, which is part of why the drug lowers blood pressure and reduces cardiac preload.

The Ketone Problem During Illness

When you are sick and not eating, your body mobilizes fat for fuel. Glucagon rises. Insulin falls. SGLT2 inhibitors amplify this shift by further lowering insulin secretion and by increasing circulating glucagon, pushing the liver toward ketone production. The kidneys, meanwhile, continue excreting glucose, so blood sugar stays deceptively normal even as ketones accumulate dangerously.

FDA issued a Drug Safety Communication in 2015 specifically warning about euglycemic DKA with SGLT2 inhibitors. The signal was not small. Cases involved hospitalization and death.

The Dehydration Problem

Osmotic diuresis from glucosuria causes you to lose sodium and water continuously. When you add fever, vomiting, diarrhea, or reduced oral intake, volume depletion compounds quickly. Reduced renal perfusion can then precipitate acute kidney injury (AKI), and empagliflozin's cardioprotective mechanism depends partly on preserved renal function.

Why Women May Notice This Differently

Baseline body water is lower in women than in men by roughly 10 percentage points, meaning the same osmotic diuresis produces proportionally more volume depletion per kilogram. Women with a smaller lean body mass, common after menopause, may experience dehydration more acutely. This is not well-studied in the primary empagliflozin literature, and the sex-disaggregated fluid-balance data from EMPA-REG OUTCOME have not been separately published. That is an evidence gap worth acknowledging.

When to Hold Empagliflozin: The Sick-Day Decision Tree

The table below provides a practical, condition-specific framework for when to hold empagliflozin. Apply the most conservative rule that fits your situation.

| Situation | Hold before | Restart after | |---|---|---| | Vomiting or diarrhea (any severity) | Immediately | 48 hours of normal intake + resolved symptoms | | Fever >38.5°C with reduced intake | Immediately | Afebrile 24 hours, eating normally | | Elective surgery (general anesthesia) | At least 3 days prior | Eating and drinking normally post-op, eGFR checked | | Emergency surgery | Hold immediately; notify surgical team | Same as elective | | IV contrast procedure (CT with contrast) | 48 hours prior | eGFR confirmed stable at 48-hour recheck | | Prolonged fasting >12 hours (not surgical) | Day of fast | Resumed normal eating | | Urinary tract infection (UTI) alone | Usually continue; ask your provider | Not applicable if continued | | Hospitalization for any reason | Hold on admission | Discharge criteria met (see below) |

The American Diabetes Association Standards of Care advise holding SGLT2 inhibitors in the setting of acute illness, major surgery, and procedures requiring contrast. The NICE type 2 diabetes guidelines echo this with explicit instruction to stop on admission to hospital.

How the Menstrual Cycle Changes Your Risk

During the luteal phase (days 15 to 28 of a typical cycle), progesterone rises and mildly impairs insulin action. If you fall ill during the luteal phase, your baseline insulin resistance is already higher, which slightly increases ketone production risk. Menstruation itself causes fluid shifts and can mimic dehydration symptoms. Track your cycle when you are unwell and mention your cycle phase to your provider.

Perimenopause and Insulin Resistance Shifts

Estrogen withdrawal in perimenopause decreases insulin sensitivity at the level of skeletal muscle and liver. One analysis of the SWAN cohort found that insulin resistance rose significantly in the late perimenopausal transition, independent of weight gain. For a woman in perimenopause, the metabolic ground is shifting week to week. When she is also acutely ill, the combination of perimenopausal insulin resistance, reduced food intake, and continued SGLT2 blockade creates a higher-than-average DKA window. Hold the drug and restart conservatively.

The Restart Protocol: Step by Step

Restarting too quickly is as dangerous as not restarting at all. These are the clinical benchmarks your provider should confirm before you take your next dose.

Step 1: Confirm Clinical Resolution

You must be eating your normal diet across at least two consecutive meals without nausea. You must be drinking your normal fluid volume, roughly 2 liters per day for most women. Your temperature must be normal for at least 24 hours. Any vomiting or diarrhea must have stopped completely.

Step 2: Confirm Renal Function

An eGFR should be checked after any significant illness, hospitalization, or procedure. Empagliflozin's glucose-lowering efficacy drops meaningfully once eGFR falls below 45 mL/min/1.73m², and the drug is not recommended for glucose control at that level, though cardiovascular and renal-protective benefits extend to lower eGFR thresholds in heart failure and CKD indications. Confirm your kidneys have recovered before resuming.

Step 3: Check Ketones if There Is Any Doubt

If your illness involved vomiting, prolonged fasting, or significant metabolic stress, a urine or blood ketone check before restarting is reasonable. A blood beta-hydroxybutyrate above 1.5 mmol/L warrants a call to your provider before you take any dose. This is not standard practice in all guidelines, but several specialist centers now recommend it for high-risk patients.

Step 4: Resume at the Same Dose

There is no evidence that titrating down and back up on restart provides any benefit. Your prior prescribed dose is the right dose. Resume the next morning after your criteria are met.

Empagliflozin Across Women's Life Stages

Reproductive Years: PCOS and Fertility Considerations

Women with polycystic ovary syndrome (PCOS) have two to three times the background insulin resistance of age-matched women without PCOS. SGLT2 inhibitors are being studied in PCOS as an off-label option, and some early data suggest improvements in androgen levels and menstrual regularity. However, if you have PCOS and are trying to conceive, empagliflozin must be stopped before any fertility treatment cycle and should be discontinued as soon as pregnancy is confirmed. The ovulatory unpredictability in PCOS means unplanned pregnancies are possible. Use reliable contraception while taking this drug.

Trying to Conceive

Discuss a discontinuation plan with your prescriber before you start trying to conceive. The FDA-approved label does not recommend empagliflozin in pregnancy. Stopping two to four weeks before a planned conception attempt gives the drug time to clear.

Pregnancy: A Mandatory Hold

The FDA advises against empagliflozin use during the second and third trimesters based on animal data showing renal toxicity and embryo-fetal development concerns. Human data are limited; most pregnancies with SGLT2 inhibitor exposure are from inadvertent first-trimester use, and outcomes data are insufficient to establish safety. The ACOG guidance on pregestational diabetes does not endorse any SGLT2 inhibitor in pregnancy, and insulin remains the standard of care for glucose management during pregnancy.

If you discover you are pregnant while taking empagliflozin, stop the drug immediately and contact your obstetric provider the same day.

Postpartum and Lactation

There are no adequate human studies on empagliflozin transfer into breast milk. Animal studies suggest the drug and its metabolites appear in milk and may affect developing renal tissue in nursing offspring. The FDA label states that empagliflozin is not recommended during breastfeeding. If you have type 2 diabetes and wish to breastfeed, work with your provider on an insulin-based or metformin-based plan for glucose management during lactation.

The postpartum period also carries a specific risk window: women with gestational diabetes have a 50% lifetime risk of progressing to type 2 diabetes, and those who develop early postpartum type 2 diabetes may be considered for empagliflozin once they have weaned. This conversation should happen with your endocrinologist or OB-GYN, not at a routine postpartum visit.

Perimenopause

Perimenopausal women with type 2 diabetes, heart failure with preserved ejection fraction (HFpEF), or CKD are among the patients who stand to gain the most from empagliflozin's cardiorenal benefits. Yet perimenopause is also a time of erratic hormonal fluctuation, weight gain, and new-onset metabolic dysfunction. Several clinical scenarios are unique to this stage.

Hot flashes cause repeated episodes of sweating and minor volume depletion. If you are having multiple hot flushes per night, consider increasing your fluid intake while on empagliflozin, particularly in hot weather.

UTI frequency often rises in perimenopause due to falling estrogen in the urogenital tissue. Empagliflozin raises UTI risk modestly by creating a glucosuria environment. Genital mycotic infections occurred in roughly 10% of women in the EMPA-REG OUTCOME trial, higher than in men. If you develop a UTI while on empagliflozin, your provider will decide case-by-case whether to hold or continue. Simple uncomplicated UTIs typically do not require holding the drug.

Post-Menopause

Post-menopausal women face accelerated cardiovascular risk and bone loss. Empagliflozin's cardiovascular protection is directly relevant. One concern specific to this group: SGLT2 inhibitors have been associated with modestly increased rates of lower-limb fractures in some trials, particularly with canagliflozin. The EMPA-REG OUTCOME data did not show a significant fracture signal with empagliflozin, but post-menopausal women with existing osteoporosis should discuss bone density monitoring with their provider.

Who This Drug Is Right For After an Illness Interruption

Strong Candidates to Restart Promptly

• Women with type 2 diabetes and established cardiovascular disease (the EMPA-REG OUTCOME population)
• Women with heart failure, regardless of ejection fraction, once euvolemia is re-established
• Women with CKD (eGFR 20 to 45 range) on empagliflozin for renal protection, provided eGFR has not fallen acutely
• Women with T2D and significant albuminuria who had been responding well to therapy

Women Who Should Wait Longer or Reconsider

• Anyone with AKI during the illness, until eGFR returns to within 20% of baseline
• Women who experienced DKA during the illness, who need a thorough specialist review before restart
• Anyone who is still in the hospital, regardless of how much better they feel
• Women in the second or third trimester of pregnancy, full stop
• Breastfeeding women

Practical Sick-Day Rules You Can Use Today

Your care team should give you written sick-day rules. If they have not, here is what the evidence supports.

Stop the drug if any of these apply:

• You have vomited even once
• You have had diarrhea more than twice in 24 hours
• You cannot keep fluids down
• You feel too unwell to eat your normal meals
• You have a fever above 38.5°C
• You are about to have surgery or a procedure requiring anesthesia
• You are about to have a scan using intravenous contrast dye

Call your provider that same day if:

• Your symptoms last more than 24 hours
• You have abdominal pain, difficulty breathing, or confusion (these could be DKA symptoms even if your glucose is normal)
• You are unsure whether your level of illness requires holding

Go to the emergency department if:

• You have nausea, vomiting, and abdominal pain together
• Your urine or blood ketones are elevated
• You feel dizzy, confused, or your breathing feels labored

The FDA label instructs patients to seek medical attention immediately if signs or symptoms of DKA occur.

Monitoring After You Restart

Once you resume empagliflozin, the following checks are appropriate in the week after a significant illness.

• Fasting glucose daily for three to five days to confirm glycemic stability
• Weigh yourself daily (sudden weight gain may signal fluid reaccumulation in heart failure patients)
• Monitor for yeast infection symptoms, as the glucosuria environment returns
• Check in with your provider at two weeks if the illness was significant (hospitalization, AKI, or DKA)

Women with heart failure and HFpEF (a condition that disproportionately affects post-menopausal women) should pay particular attention to daily weights. EMPEROR-Reduced and EMPEROR-Preserved trials confirmed empagliflozin's benefit in both HF phenotypes, but fluid management requires attention in the rebound period after illness-related dehydration.

The Evidence Gap: What We Do Not Know About Women and SGLT2 Restart

Women made up only approximately 25% of the EMPA-REG OUTCOME trial population. The sick-day rules described here are largely extrapolated from the overall trial safety data, pharmacokinetic studies, and expert consensus rather than from prospective studies specifically in women during acute illness.

Dr. Elena Vasquez, MD, WomanRx Editorial Board (Reproductive Endocrinology and Women's Metabolic Health), reviewed this article and notes: "In clinical practice, I see perimenopausal women on empagliflozin who are genuinely unsure what to do when they get a stomach bug. The sex-disaggregated sick-day data simply do not exist. We are applying population-level rules to a physiological context that is measurably different in women, particularly regarding volume regulation, and the field needs prospective studies in this group."

What we do know is that underdosing (unnecessary prolonged holds) costs women the cardiovascular, renal, and glycemic benefits that EMPA-REG OUTCOME demonstrated. Overdosing (premature restart) risks DKA and AKI. Navigating that narrow window is the clinical task.

Contraception Requirements While Taking Empagliflozin

Empagliflozin is not a teratogen in the same category as warfarin or isotretinoin, but its fetal risk in the second and third trimester is established enough that reliable contraception is recommended for any woman of reproductive age taking this drug who does not want to become pregnant.

Combined hormonal contraceptives (CHC) do not interact pharmacokinetically with empagliflozin at clinically significant levels. However, CHCs may modestly raise blood glucose in susceptible women, which is worth monitoring in someone with T2D. Progestin-only pills, IUDs (both hormonal and copper), and barrier methods are all acceptable options. Discuss the best fit with your gynecologist.

ACOG Practice Bulletin on contraceptive use in women with chronic medical conditions provides category-based guidance for women with diabetes choosing contraception.